Johnathan Maher

VP, Head of Medical Affairs @Day One Biopharmaceuticals

Phoenix, AZ, US
MOBILE NUMBERS
+17•••••••13

Signup · Get unlimited contacts

WORK HISTORY

Jan 2025 — Present

VP, Head of Medical Affairs @Day One Biopharmaceuticals

View department →

Led Medical Affairs function within R&D for commercial-stage rare oncology company with on-market asset OJEMDA (tovorafenib) in pediatric low-grade glioma (pLGG) and expanding pipeline. Managed the organization across in-field MSLs and HQ strategic/operations functions.Defined and operationalized a new Medical Affairs vision — establishing organizational structure across five core domains (Evidence Generation & Publications, Medical Strategy, Medical Review & Information, Field Medical/MSLs, Medical Operations & Analytics) and positioning Medical Affairs as a key strategic partner at the Executive governance level

EDUCATION

N/A

University of Miami Miller School of Medicine

PhD, Molecular Cell and Developmental Biology

N/A

Virginia Tech

BS, Food Science

SKILLS

NeurologyMedical WritingMedicineMetabolismClinical DevelopmentBiotechnologyClinical TrialsPharmaceutical IndustryVaccinesPublication PlanningMedical AffairsMedical CommunicationsQuality AssuranceScientific CommunicationsOncologyPharmacovigilanceRegulatory AffairsLifesciencesTherapeutic AreasLife SciencesHematologyRegulatory SubmissionsRegulationsClinical ResearchDrug DevelopmentCancerBiopharmaceuticalsInfectious DiseasesImmunology

ABOUT JOHNATHAN MAHER

Accomplished Medical Affairs leader with 20+ years of oncology experience spanning solid tumors and hematologic malignancies in both common (prostate, breast, PDAC, NSCLC, RCC, CLL) and rare (pLGG, AML) cancers. Proven track record building high-performing Medical Affairs organizations from the ground up and positioning the function as a strategic enterprise partner. Deep expertise in launch readiness, cross-functional collaboration, organizational transformation, KOL engagement, and strategic evidence generation. Adept at translating scientific complexity into strategic action and building durable infrastructure that scales from early development through commercialization.Signature accomplishments:• Established a new Medical Affairs framework at Day One Biopharmaceuticals, stabilizing and transforming the function into a strategic enterprise partner at a pivotal commercial stage for OJEMDA (tovorafenib) and Day One• Led Global Medical Affairs for venetoclax (VENCLEXTA/VENCLYXTO) launch across CLL and MM at AbbVie, earning four President\'s Awards including the R&D President\'s Award

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.